

**I. REMARKS:**

**A. Status of the Claims**

The application was originally filed with claims 1-4. Claims 1-4 were rejected in an Office Action mailed September 28, 2004. Claim 1 was amended and claim 5 was added in a Response to Office Action filed on January 28, 2005. Therefore, claims 1-5 were pending at the time of the current Restriction Requirement.

**B. Species Election**

The Restriction Requirement states that the pending claims are directed to a number of patentably distinct species, including glaucoma, dry AMD, RP and other forms of heterodegenerative retinal disease, retinal detachment and tears, macular pucker, ischemia affecting the outer retina, cellular damage associated with diabetic retinopathy and retinal ischemia, damage associated with laser therapy, trauma, surgical or light induced iatrogenic retinopathy and preservation of retinal transplantation. The Action acknowledges that claim 1 is generic and requests that Applicant elect a single disclosed species for prosecution. Applicant elects the species of dry AMD. For examination purposes, claims 1, 2, 3 and 5 read on the elected species.

**C. Conclusion**

This is submitted to be a complete response to the outstanding Action. Based on the foregoing arguments, the claims are believed to be in condition for allowance; a notice of allowability is therefore respectfully requested.

Serial No.: 10/694,309 (Conf. #3568)  
Filing Date: 27 October 2003  
Page 3

The Examiner is invited to contact the undersigned attorney at (817) 551-4321 with any questions, comments or suggestions relating to the referenced patent application.

Respectfully submitted,



Teresa J. Schultz  
Reg. No. 40,526  
Attorney for Applicants

ALCON RESEARCH, LTD.  
6201 S. Freeway, Q-148  
Fort Worth, TX 76134-2099  
(817) 551-4321

Date: 31 May 2005